Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin

Journal of Clinical Pharmacology

Volumn 58, Issue 3, 2018, Pages 377-385

  Brady, Jessica A ^a   Hallow, K Melissa ^a,b  

^a University of Georgia   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

canagliflozin; mechanistic model; sodium glucose cotransporter 2 inhibitors; type 2 diabetes; urinary glucose excretion

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; SODIUM;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE LEVEL; GLUCOSE REABSORPTION; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HUMAN; INSULIN CLEARANCE; KIDNEY BLOOD FLOW; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; SODIUM ABSORPTION; SODIUM LOAD; URINARY EXCRETION; BIOLOGICAL MODEL; BLOOD; DRUG EFFECT; KIDNEY; METABOLISM; PHARMACOLOGY;

CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MODELS, BIOLOGICAL; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85034020611     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.1030     Document Type: Article

References (16)

1. Bjornstad P, Cherney DZ, Snell-Bergeon JK, et al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with type 1 diabetes. Nephrol Dial Transplant. 2015;30(10):1706-1711.
2. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351-375.
3. Hallow KM, Gebremichael Y, Helmlinger G, Vallon V. Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol. In press.
4. Vallon V, Blantz RC, Thomson S. Homeostatic efficiency of tubuloglomerular feedback is reduced in established diabetes mellitus in rats. Am J Physiol. 1995;269(6 Pt 2):F876-F883.
5. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10(12):2569-2576.
6. Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grunfeld JP. Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int. 1990;37(4):1126-1133.
7. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
8. Jauslin PM, Silber HE, Frey N, et al. An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol. 2007;47(10):1244-1255.
9. Jauslin PM, Frey N, Karlsson MO. Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes. J Clin Pharmacol. 2011;51(2):153-164.
10. Silber HE, Jauslin PM, Frey N, Gieschke R, Simonsson WSH, Karlsson MO. An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol. 2007;47(9):1159-1171.
11. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669-672.
12. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53(6):601-610.
13. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol. 2003;14(2):530-537.
14. Petrykiv SI, Laverman GD, Zeeuw D, Heerspink HJ. The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients. Diabetes Obes Metab. In press.
15. Layton AT, Vallon V, Edwards A. Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol. 2016;310(11):F1269-F1283.
16. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(suppl 2):S165-S171.